Myriad Genetics announces five research collaborations to study MRD testing

Myriad Genetics announced a series of ongoing research collaborations to study the use of molecular residual disease, or MRD, testing in breast cancer using Myriad’s Precise MRD test. A study to determine whether circulating tumor DNA, or ctDNA, level may predict magnitude of response to pembrolizumab and hormonal therapy in patients with HR-positive inflammatory breast cancer who did not achieve pathological complete response at the time of surgery, led by Bora Lim, at The University of Texas MD Anderson Cancer Center. A study to evaluate whether ctDNA levels correlate with nodal involvement in patients with newly diagnosed HR-positive breast cancer and, if so, how the correspondence may be used to aid in surgical decision making, led by Anna Weiss, at The University of Rochester Medical Center. The multicenter, prospective MONITOR-breast study to determine the association of ctDNA levels to both neoadjuvant and adjuvant therapy in patients with newly diagnosed breast cancer across all subtypes. The study will involve 650 patients and will assess the prognostic potential of ctDNA and the lead time of detecting recurrence earlier ahead of standard-of-care imaging. The multicenter, prospective study JBCRG-C11 to evaluate the maintenance of complete response with trastuzumab deruxtecan in HER2-positive advanced or metastatic breast cancer patients and whether ctDNA can be used to optimally guide therapy, led by Yoichi Naito, of the National Cancer Center Hospital East in Japan. A study in partnership with Aptitude Health to assess ctDNA levels in high-risk patients at diagnosis, during neoadjuvant treatment, and following surgery in community oncology settings.